70 research studies
Research studies and participants in Alzheimer’s disease and mild cognitive impairment (MCI) research studies conducted by Lilly.
Collaborations: Lilly's Alzheimer's Research
Lilly’s research often involves teamwork with other parties that share our passion for finding effective treatments for Alzheimer's disease. We work with academic institutions, government entities, and advocacy organizations. This work enables us to harness scientific breakthroughs and the latest knowledge about the disease. Through these collaborations, we discover together.
Our collaborative research studies include:
Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) Research Study
The A4 research study examines whether a study drug targeting beta amyloid can help slow memory loss in some people. The research involves people who do not have symptoms of Alzheimer’s disease but do already have an increased number of brain plaques. These plaques are a potential sign of Alzheimer’s disease. The A4 research study is funded by the National Institute on Aging and Lilly, as well as several philanthropic organizations.
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Research Study
The DIAN-TU research study is a global research partnership studying a rare form of Alzheimer’s disease that runs in families. It is researching two study drugs that target beta amyloid. The National Institutes of Health, philanthropic contributions, Lilly, and Roche funded this research study.
The Science: Lilly’s Alzheimer’s Research
Lilly is studying many investigational drugs and imaging tools in Alzheimer’s research studies. Many of these study drugs are intended to target beta amyloid and tau. Beta amyloid and tau are pieces of protein, and may be biomarkers for Alzheimer’s disease. A biomarker is also called a marker or indicator. It is a measurable sign of some state or condition. For example, cholesterol level is a biomarker for coronary artery disease. Similarly, beta amyloid and abnormal tau proteins may be biomarkers for Alzheimer’s disease. We are also studying imaging tools that may help researchers see these markers in the brain.Next Section arrow_downward
"I’d like to find something [that] could stop it [Alzheimer’s] from getting worse, and find out what’s causing it." Nola